+++ Ihre Meinung ist uns wichtig: Wie zufrieden sind Sie mit finanzen.ch? - Hier an unserer Umfrage teilnehmen! +++ -w-
News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
16.09.2019 14:29:23

Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout deal

Shares of Alder BioPharmaceuticals Inc. blasted 83% higher on very heavy volume in premarket trading Monday, after the developer of migraine treatment eptinezumab agreed to be bought out by Denmark-based H. Lundbeck A/S in a deal valued at $1.95 billion. Trading volume was already more than 4.6 million shares an hour ahead of the open, compared with the full-day average of about 638,000 shares. Under terms of the deal, Lundbeck will commence a tender offer of $18 for each Alder share outstanding, which is 79% above Friday's closing price of $10.06. Alder shareholders will also receive a contingent value right (CVR) that entitles them to an additional $2 a share if Alder's eptinezumab is approved by the European Medicines Agency (EMA). At $20 a share, Alder's market capitalization would be $1.67 billion. Alder's stock hasn't closed at $20 or above since May 2017. The stock has lost 44.7% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has lost 11.5% and the S&P 500 has gained 3.5%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Weiter zum vollständigen Artikel bei "Market Watch"

Analysen zu Alder BioPharmaceuticals Incmehr Analysen

12.10.18 Alder BioPharmaceuticals Neutral Mizuho
07.08.18 Alder BioPharmaceuticals Buy Stifel, Nicolaus & Co., Inc.
27.06.18 Alder BioPharmaceuticals Buy Needham & Company, LLC
12.01.18 Alder BioPharmaceuticals Buy Canaccord Adams
09.01.18 Alder BioPharmaceuticals Buy Mizuho

Eintrag hinzufügen

Zahlenflut und «Neverending Story – Brexit» | BX Swiss TV

Aktien in diesem Artikel

Finanzen.net News